Amgen and Duke Clinical Research Institute initiated first large-scale registry to evaluate real-world lipid management
On Nov. 15, 2019, Amgen and the Duke Clinical Research Institute announced plans to initiate first large-scale registry to evaluate real-world lipid management and the effectiveness of PCSK9 inhibitors, the cvMOBIUS Study.
Tags:
Source: Amgen
Credit:
